title: A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy.
abstract: Previous clinical evaluation of FK506 in renal transplantation has demonstrated equivalent patient and graft survival when compared with cyclosporine-based regimens. However, lower steroid and anti-hypertensive mediation requirements and lower serum cholesterol levels have been seen in patients receiving FK506. In August, 1991, a prospective, randomized trial was begun, comparing FK506/prednisone with FK506/azathioprine/prednisone. Two-hundred-and-four adults were entered into this trial between August 1, 1991, and October 11, 1992. The mean recipient age was 43.8 +/- 13.7 years, with a range of 17.6-78.0 years. Sixty-one (30%) recipients received a 2nd, 3rd or 4th transplant, while 35 (17%) had a PRA greater than 40% at the time of transplant. Thirty-three (16%) of the transplants were in recipients over 60 years of age, Thirteen percent of the kidneys were from living donors; 13% of the cadaveric kidneys were from pediatric donors less than 3 years of age and were transplanted en bloc. The mean cold ischemia time was 31.4 +/- 8.4 hours, and the mean donor age was 34 +/- 2.10 years, with a range from 4 months to 75 years. With a mean follow-up of 9 +/- 4 months, the 1-year actuarial patient survival is 93%; for the two-drug group it is 95%, and for the three-drug group it is 91% (p = NS). One-year actuarial graft survival is 86%; in the two-drug group it is 90%, while in the three-drug group it is 82% (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Pittsburgh Transplantation Institute, Dept. of Surgery, University of Pittsburgh Health Science Center of Pittsburgh, PA, U.S.A.
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: M
authors.initials: M
authors.lastname: Jordan
authors.forename: V
authors.initials: V
authors.lastname: Scantlebury
authors.forename: C
authors.initials: C
authors.lastname: Vivas
authors.forename: J
authors.initials: J
authors.lastname: Fung
authors.forename: J
authors.initials: J
authors.lastname: McCauley
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
authors.forename: A J
authors.initials: AJ
authors.lastname: Demetris
authors.forename: W
authors.initials: W
authors.lastname: Irish
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use*; D002102:Cadaver; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000453:epidemiology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
chemical_list: D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus